Ann: CLINUVEL renews share buy-back program, page-72

Let's compare your statements on Clinuvel who are valued at just $300 Million while making close to $40 Million NPAT annually to Disc who are losing $1 Million every two days while being valued at $2.5 Billion!

- One product (scenesse) Zero approved Products at Disc
- approx 400-500 patients Zero patients
- market saturation Hoping to enter the 'saturated' EPP market with their lead product when we don't even know if it works for EPP
- market competition around the corner Disc is the competition who are 'around the corner' but have no blockbusters in phase 3
- no ip I believe Disc have to pay Royalties if successful to whoever they purchased their IP from
- no invest in R&D Disc running no blockbuster Phase 3s but burning an extraordinary amount of cash
- no insider buyings Enormous insider selling at Disc - could someone post the amounts who know SEC filings

Interesting risk/reward paradox with these two.

All IMO DYOR